alexa Delivery Of HIV Immunogens To Mucosal Immune System Using An Oral Inactivated Cholera Vaccine
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Ali Azizi
Accepted Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.022
Abstract
Over the past two decades, several oral vehicle delivery systems have been developed to address these challenges and deliver HIV antigens to the target cells in the mucosal immune system. However, only a limited number of orally administered vaccines against HIV-1 have been tested in human trials.We have previously developed a multivalent HIV vaccine based on env and gag hypervariable regions. Despite a broad cellular and humoral immune response in mice and macaques, IgA and IgG antibody titers were suboptimal in mucosal sites. In an attempt to increase the antibody titers in mucosal sites, this vaccine candidate was entrapped into an orally delivered lipid-based system. Our results showed that entrapment of inactivated Vibrio cholera, a component in the structure of Dukoral vaccine into this candidate oral vehicle HIV delivery system, is able to induce a more rigorous humoral immune response against HIV-1 in the systemic compartment. We further investigated the mechanism of Dukoral vaccine as a potential stimulator in induction of immune response by immunizing TLR-2-, TLR-4-, MyD88- and Trif-deficient mice. We are hopeful that these findings will lead to development of more precisely-designed oral vaccines in the future.
Biography
Ali Azizi has received his Ph.D. from the Department of Microbiology and Immunology at University of Ottawa. After graduation, he joined National Research Council of Canada as a Post-doctoral Fellow. Following his fellowship, Ali joined Variation Biotechnologies and directed several pre-clinical vaccine studies in North America or Overseas. Afterwards, he joined the Department of Pathology and Laboratory Medicine at the University of Ottawa as an Adjunct (Assistant) Professor. In 2010, Ali joined Sanofi Pasteur, the largest vaccine company dedicated to the design and development of human vaccine. He is currently involved in several human vaccine phase trials. He is also acting as a part-time Lecturer at the University of Toronto. To date, Dr. Azizi has published over 20 scientific articles in peer-reviewed journals, authored a few books, and developed several international patents. He has been acting as a reviewer for several prestigious journals and international conferences. He is also served as a grant reviewer for several governmental organizations including CIHR.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords